Brings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences
Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness ...
Quanterix Corporation (Nasdaq: QTRX) , a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46 ...
Quanterix Corporation (Nasdaq: QTRX) , a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its...
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on July 15, 2026, an inducement grant (the “Inducement...
Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing New peer-reviewed and AAIC data reinforce the...
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that...
Quanterix Corporation (Nasdaq: QTRX) , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler...
Strategic Leadership Addition Signals Drive to Expand Diagnostics Business
Quanterix Corporation (Nasdaq: QTRX) , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate...